Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed B-Cell Non Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03870945
What this trial is testing

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

Who this might be right for
B-cell Non Hodgkin Lymphoma
Miltenyi Biomedicine GmbH 12
Testing effectiveness (Phase 2)Ended earlyNCT03093831
What this trial is testing

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Who this might be right for
Lymphoma, B-Cell, Marginal Zone
National Cancer Centre, Singapore 5
Testing effectiveness (Phase 2)Study completedNCT04323657
What this trial is testing

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Non Hodgkin LymphomaAcute Lymphoblastic LeukemiaDiffuse Large B Cell Lymphoma+3 more
TCR2 Therapeutics 6
Very early researchActive Not RecruitingNCT04161248
What this trial is testing

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Canadian Cancer Trials Group 40
Testing effectiveness (Phase 2)Ended earlyNCT02592876
What this trial is testing

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma, B-cellLymphoma, Large B-Cell, DiffuseLymphoma, Follicular, Grade 3b+1 more
Seagen Inc. 81
Early research (Phase 1)Study completedNCT03939026
What this trial is testing

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Who this might be right for
Relapsed/Refractory Large B Cell LymphomaRelapsed/Refractory Follicular Lymphoma
Allogene Therapeutics 50
Very early researchLooking for participantsNCT04227015
What this trial is testing

CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
He Huang 72
Very early researchUnknownNCT06045585
What this trial is testing

JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Guangdong Second Provincial General Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT02282358
What this trial is testing

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Who this might be right for
LymphomaRelapsed and RefractoryDiffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center 7
Not applicableActive Not RecruitingNCT03656835
What this trial is testing

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+1 more
Ohio State University Comprehensive Cancer Center 73
Large-scale testing (Phase 3)Study completedNCT00002456
What this trial is testing

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma
Fred Hutchinson Cancer Center
Early research (Phase 1)Looking for participantsNCT07225439
What this trial is testing

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more
Paolo Caimi, MD 15
Testing effectiveness (Phase 2)Ended earlyNCT02983097
What this trial is testing

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma Grade III (FL III°)Mantle Cell Lymphoma (MCL), Blastoid Variant+2 more
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 34
Testing effectiveness (Phase 2)Study completedNCT00622388
What this trial is testing

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Who this might be right for
Lymphoma, Large-Cell, Diffuse
GlaxoSmithKline 81
Testing effectiveness (Phase 2)Looking for participantsNCT06542250
What this trial is testing

Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Who this might be right for
B-cell Malignancies
AstraZeneca 174
Testing effectiveness (Phase 2)Study completedNCT00373646
What this trial is testing

Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

Who this might be right for
MALT Lymphoma
Medical University of Vienna 8
Testing effectiveness (Phase 2)Study completedNCT00156013
What this trial is testing

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, B-CellLymphoma, Non-Hodgkin
Oncology Specialists, S.C. 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT03075696
What this trial is testing

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 940
Testing effectiveness (Phase 2)Study completedNCT01562990
What this trial is testing

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Who this might be right for
Diffuse Large B-Cell Lymphoma
The Lymphoma Academic Research Organisation 11
Early research (Phase 1)UnknownNCT04796688
What this trial is testing

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaChronic Lymphoblastic LeukemiaB-cell Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 27
Next Page